$6.64
Price
$122M
Market Cap
—
P/E Ratio
-1.3
Forward P/E
$-14.70
EPS (TTM)
—
Dividend Yield
$46M
Cash
$195M
Total Debt
18M
Shares Out
$3.51
$10.76
52-Week Range
Institutional Ownership of KARYOPHARM THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for KARYOPHARM THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for KARYOPHARM THERAPEUTICS INC
6 Months Insider Sentiment
Buy $0
Sell $0
0
Buys
0
Sells
+0
Net
6
Grants
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | Kristin Abate | Chief Accounting Officer | GRANT | 12.8K | — | — |
| Oct 15, 2025 | Lori Macomber | EVP, CFO & Treasurer | GRANT | 43.6K | — | — |
| Oct 15, 2025 | Michael Mano | SVP, General Counsel&Secretary | GRANT | 43.6K | — | — |
| Oct 15, 2025 | Richard A. Paulson | President and CEO | GRANT | 114.3K | — | — |
| Oct 15, 2025 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | GRANT | 43.6K | — | — |
| Oct 15, 2025 | Stuart Poulton | EVP, Chief Development Officer | GRANT | 39.7K | — | — |